免疫蛋白诊断检测市场－全球产业规模、份额、趋势、机会及预测（依检测方法、技术、应用、通路、最终用途、地区及竞争格局划分），2021-2031年

全球免疫蛋白诊断测试市场预计将从 2025 年的 108.8 亿美元成长到 2031 年的 169.3 亿美元，复合年增长率为 7.65%。

此诊断领域涉及对特定蛋白质（例如免疫球蛋白和细胞激素）进行定性和定量检测，以识别从自体免疫疾病到感染疾病等多种健康问题。推动该市场成长的关键因素是慢性病在全球日益普遍，以及早期医疗介入对促进患者復原的重要性日益凸显。此外，人口老化也显着推动了对精准诊断工具的需求，因为老年人通常需要更频繁、更深入的临床监测。

儘管市场环境有利，但实施自动化诊断系统的高昂成本仍然是市场准入的一大障碍，尤其是在医疗资源有限的地区。美国癌症协会预测，到2024年，美国将新增约2,001,140例癌症病例，显示需要进行此类检测的疾病负担日益加重。如此高的发病率预测凸显了建立强大的诊断检测基础设施以支持及时有效的患者照护策略的必要性。

市场驱动因素

慢性病和感染疾病率的上升是全球免疫蛋白诊断检测市场的主要驱动力。这种增长催生了对能够检测特定生物标记（例如细胞激素和免疫球蛋白）的精准免疫分析的需求，这些生物标记对于确诊和追踪疾病进展至关重要。随着传染性病原体的变异和慢性病的日益普遍，医疗系统高度依赖这些工具来进行有效的患者管理和早期检测。世界卫生组织（世卫组织）在其2024年4月发布的《2024年全球肝炎报告》中强调了感染疾病的严重性，报告指出，2022年病毒性肝炎相关死亡人数预计将达到130万，这凸显了建立强大的检测能力以应对这一全球健康风险的紧迫性。

此外，免疫检测平台的技术进步和就地检验的广泛应用，透过提高检测的便利性和速度，正在加速市场成长。现代实验室正在部署高通量分析仪，以处理与各种慢性疾病相关的大量检测。例如，美国心臟协会报告称，到2024年，约有48.6%的美国成年人将患有某种形式的心血管疾病，这使得蛋白质生物标记对于该疾病的风险评估至关重要。因此，诊断设备製造商获得了可观的收入。根据丹纳赫公司于2024年2月发布的2023年度报告，该公司诊断设备部门预计将创造96亿美元的收入，从而确保其诊断能力的扩充性，以满足全球不断增长的临床需求。

市场挑战

全球免疫蛋白诊断检测市场成长的主要障碍之一是实施自动化诊断系统的高成本。先进的免疫蛋白分析仪需要大量的初始资本投入，不仅包括设备购置，还包括安装、校准和人员培训费用。这种资本投入构成了进入门槛，尤其对于预算有限的小规模实验室和医疗机构而言更是如此。因此，许多机构推迟采用最新的诊断工具，被迫继续使用速度和效率都远不及现代自动化平台的旧系统。

近期医院支出方面的产业统计数据凸显了推迟关键技术升级的趋势。根据美国医院协会2024年的报告，由于医疗机构为应对不断上涨的营运成本而推迟采购决策，医疗基础设施和设备资本投资的平均使用年限同比增长了7.1%。这种财政谨慎的做法使得医疗机构难以资金筹措资金用于基础设施更新，限制了高通量免疫蛋白检测解决方案的普及，并直接阻碍了市场扩张。

市场趋势

将人工智慧 (AI) 和机器学习融入诊断工作流程，显着提升了营运效率和分析准确性，从而正在深刻改变全球免疫蛋白诊断检测市场。检查室越来越多地使用 AI 演算法来分析复杂的蛋白质模式，并实现数位病理切片评估的自动化，从而最大限度地减少人为错误，并更快地提供结果。这种技术整合使得处理精准医疗所需的大型资料集成为可能，尤其是在免疫学和肿瘤学领域。罗氏公司在 2024 年 9 月发布的题为「罗氏推进 AI 驱动的癌症诊断」的新闻稿中，就反映了这一趋势。该公司在新闻稿中宣布，已在其数位病理生态系统中整合了 20 多种新的 AI 演算法，以帮助临床医生识别特定的肿瘤分化等级和生物标记。

此外，直接面向消费者 (DTC) 和居家检体采集模式的成长，标誌着医疗保健服务正朝着去中心化、以患者为中心的方向发生重要转变。主要市场参与者正在迅速扩展其产品和服务，允许个人在线上购买某些健康和免疫蛋白检测，从而绕过传统的临床中介机构，促进主动健康管理。这种诊断的普及化正在推动在传统医院环境之外进行的检测数量显着增加。例如，Quest Diagnostics 在 2024 年 6 月发布的 2023 年企业责任报告中揭露，其面向消费者的平台上提供的检测数量几乎翻了一番，降低了患者获取快速便捷诊断资讯的门槛。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球免疫蛋白诊断检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（补体系统蛋白诊断试验、游离轻链诊断试验、肝珠蛋白诊断试验、免疫球蛋白诊断试验、前白蛋白诊断试验、C反应蛋白（CRP）诊断试验）
  • 依技术（免疫测量、酵素免疫分析法测定法、化学发光测定、萤光、免疫比浊法、免疫蛋白电泳）
  • 依应用领域（传染病检查、肿瘤检测、内分泌检测、毒性检测、过敏检测、自体免疫疾病检测）
  • 按分销管道（直接竞标和零售）
  • 透过申请（医院/诊所、诊断检查室等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美免疫蛋白诊断检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲免疫蛋白诊断检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区免疫蛋白质诊断检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲免疫蛋白诊断检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲免疫蛋白诊断检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球免疫蛋白诊断检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Aurora Biomed Inc.
• Tecan Trading AG
• Promega Corporation
• Charles River Laboratories International, Inc.
• Creative Biolabs, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Immunoprotein Diagnostic Testing Market is projected to expand from USD 10.88 Billion in 2025 to USD 16.93 Billion by 2031, reflecting a CAGR of 7.65%. This diagnostic field involves the qualitative and quantitative examination of specific proteins, including immunoglobulins and cytokines, to identify a spectrum of health issues ranging from autoimmune diseases to infections. Key drivers fueling this market growth include the increasing global prevalence of chronic diseases and the vital need for early medical intervention to enhance patient recovery. Additionally, the aging global population significantly bolsters the demand for precise diagnostic measures, as this demographic typically necessitates frequent and thorough clinical monitoring.

Despite these favorable growth conditions, the substantial costs required to implement automated diagnostic systems create a significant barrier to market entry, particularly in regions with restricted healthcare funds. To demonstrate the rising disease burden that mandates these tests, the American Cancer Society projected in 2024 that approximately 2,001,140 new cancer cases would occur in the United States. This high volume of anticipated disease incidence underscores the critical necessity for a strong diagnostic testing infrastructure to support timely and effective patient care strategies.

Market Driver

The rising incidence of chronic and infectious diseases acts as a major driver for the Global Immunoprotein Diagnostic Testing Market. This increase creates a demand for accurate immunological assays capable of detecting specific biomarkers, such as cytokines and immunoglobulins, which are crucial for confirming diagnoses and tracking disease development. As infectious agents mutate and chronic illnesses become more common, healthcare frameworks depend heavily on these tools for efficient patient management and early detection. Highlighting the gravity of infectious diseases, the World Health Organization reported in its 'Global Hepatitis Report 2024' from April 2024 that viral hepatitis-related deaths climbed to an estimated 1.3 million in 2022, emphasizing the urgent need for strong testing frameworks to handle global health risks.

Furthermore, technological progress in immunoassay platforms and the increasing use of point-of-care testing are accelerating market growth by enhancing accessibility and speed. Modern laboratories are adopting high-throughput analyzers to manage the large testing volumes associated with widespread chronic conditions. For instance, the American Heart Association reported in 2024 that roughly 48.6% of adults in the United States suffered from some form of cardiovascular disease, a condition that relies heavily on protein biomarkers for risk assessment. Consequently, diagnostic manufacturers are seeing significant financial returns; Danaher Corporation's '2023 Annual Report' from February 2024 noted that its Diagnostics segment yielded revenues of $9.6 billion, ensuring that diagnostic capacities remain scalable to meet growing global clinical needs.

Market Challenge

A major obstacle to the growth of the Global Immunoprotein Diagnostic Testing Market is the high cost associated with implementing automated diagnostic systems. Advanced immunoprotein analyzers demand significant upfront capital investment, covering not just the purchase of equipment but also costs for installation, calibration, and staff training. This financial requirement establishes a difficult barrier to entry, especially for smaller laboratories and healthcare facilities with limited budgets. As a result, many organizations are compelled to delay acquiring modern diagnostic tools, choosing instead to rely on older systems that may lack the speed or efficiency of contemporary automated platforms.

The tendency to delay essential technological upgrades is highlighted by recent industry statistics concerning hospital expenditures. According to the 'American Hospital Association' in '2024', the average age of capital investments for medical infrastructure and equipment rose by 7.1% over the previous year as facilities postponed purchasing decisions to cope with rising operating costs. This financial caution directly impedes market expansion, as the inability of healthcare providers to fund updated infrastructure limits the adoption of high-throughput immunoprotein testing solutions.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into diagnostic workflows is significantly transforming the Global Immunoprotein Diagnostic Testing Market by improving operational efficiency and analytical accuracy. Laboratories are increasingly utilizing AI algorithms to analyze complex protein patterns and automate the assessment of digital pathology slides, thereby minimizing human error and accelerating the delivery of results. This convergence of technologies facilitates the processing of massive datasets necessary for precision medicine, especially within immunology and oncology. Confirming this trend, Roche announced in a September 2024 press release titled 'Roche advances AI-driven cancer diagnostics' that it had integrated over 20 new AI algorithms into its digital pathology ecosystem to assist clinicians in identifying specific tumor gradings and biomarkers.

Additionally, the growth of Direct-to-Consumer and At-Home Sample Collection Models marks a significant shift toward decentralized, patient-focused healthcare access. Leading market players are rapidly expanding their service offerings to enable individuals to purchase specific wellness and immunoprotein tests online, sidestepping traditional clinical intermediaries and encouraging proactive health management. This democratization of diagnostics is fueling substantial volume increases outside conventional hospital environments. Demonstrating this rapid uptake, Quest Diagnostics revealed in its '2023 Corporate Responsibility Report' from June 2024 that the company had nearly doubled the number of tests offered on its consumer-facing platform, thereby lowering entry barriers for patients looking for immediate and convenient diagnostic insights.

Key Market Players

• Agilent Technologies, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Aurora Biomed Inc.
• Tecan Trading AG
• Promega Corporation
• Charles River Laboratories International, Inc.
• Creative Biolabs, Inc

Report Scope

In this report, the Global Immunoprotein Diagnostic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoprotein Diagnostic Testing Market, By Test

• Complement System Proteins Diagnostic Tests
• Free Light Chain Diagnostic Tests
• Haptoglobin Diagnostic Tests
• Immunoglobulin Diagnostic Tests
• Prealbumin Diagnostic Tests
• C-Reactive Protein (CRP) Diagnostic Tests

Immunoprotein Diagnostic Testing Market, By Technology

• Radioimmunoassay
• Enzyme Based Immunoassay
• Chemiluminescence Assay
• Immunofluorescence Assay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis

Immunoprotein Diagnostic Testing Market, By Application

• Infectious Disease Testing
• Oncology Testing
• Endocrine Testing
• Toxicology Testing
• Allergy Testing
• Autoimmune Disease Testing

Immunoprotein Diagnostic Testing Market, By Distribution Channel

• Direct Tender
• Retail Sales

Immunoprotein Diagnostic Testing Market, By End Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Immunoprotein Diagnostic Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoprotein Diagnostic Testing Market.

Available Customizations:

Global Immunoprotein Diagnostic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoprotein Diagnostic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test (Complement System Proteins Diagnostic Tests, Free Light Chain Diagnostic Tests, Haptoglobin Diagnostic Tests, Immunoglobulin Diagnostic Tests, Prealbumin Diagnostic Tests, and C-Reactive Protein (CRP) Diagnostic Tests)
  • 5.2.2. By Technology (Radioimmunoassay, Enzyme Based Immunoassay, Chemiluminescence Assay, Immunofluorescence Assay, Immunoturbidity Assay, and Immunoprotein Electrophoresis)
  • 5.2.3. By Application (Infectious Disease Testing, Oncology Testing, Endocrine Testing, Toxicology Testing, Allergy Testing, and Autoimmune Disease Testing)
  • 5.2.4. By Distribution Channel (Direct Tender and Retail Sales)
  • 5.2.5. By End Use (Hospitals & Clinics, Diagnostic Laboratories and Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Immunoprotein Diagnostic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Distribution Channel
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Distribution Channel
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Distribution Channel
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico Immunoprotein Diagnostic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Distribution Channel
      • 6.3.3.2.5. By End Use

7. Europe Immunoprotein Diagnostic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Distribution Channel
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Distribution Channel
      • 7.3.1.2.5. By End Use
  • 7.3.2. France Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Distribution Channel
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Distribution Channel
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Distribution Channel
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain Immunoprotein Diagnostic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Distribution Channel
      • 7.3.5.2.5. By End Use

8. Asia Pacific Immunoprotein Diagnostic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Distribution Channel
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Distribution Channel
      • 8.3.1.2.5. By End Use
  • 8.3.2. India Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Distribution Channel
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Distribution Channel
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Distribution Channel
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia Immunoprotein Diagnostic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Distribution Channel
      • 8.3.5.2.5. By End Use

9. Middle East & Africa Immunoprotein Diagnostic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Distribution Channel
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Distribution Channel
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Distribution Channel
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa Immunoprotein Diagnostic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Distribution Channel
      • 9.3.3.2.5. By End Use

10. South America Immunoprotein Diagnostic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Distribution Channel
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Distribution Channel
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Distribution Channel
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina Immunoprotein Diagnostic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Distribution Channel
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunoprotein Diagnostic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. PerkinElmer, Inc.
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. Aurora Biomed Inc.
• 15.7. Tecan Trading AG
• 15.8. Promega Corporation
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Creative Biolabs, Inc

16. Strategic Recommendations

17. About Us & Disclaimer